Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer

Objective： The aim of this study was to evaluate the efficacy and safety profile of DeFazio （S-l） combined with oxaliplatin against unresectable advanced or metastatic gastric cancer. Methods： Oxaliplatin was given intravenously at 130 mg/m2 for 2 h on dl and S-1 was administered bid. at 80 mg/m2/day on d1-14 followed by a 7-day rest during the 3-week schedule. Results： All 62 patients were assessed for efficacy and adverse events. The response and disease control rates were 47.3% and 80.8%, respectively. The median time to progression was 7.8 months, and the median overall survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia （11.3%）, thrombocytopenia （9.7%） and gastrointestinal reactions （6.5%）. Conclusion： The SOX regimen （oxaliplatin, 130 mg/m2 d l; S-1, 80 mg/m2/day, bid. d1-14, q3w） provide a favorable efficacy and safety profile in patients with advanced gastric cancer.     

Clinical observation of capecitabine plus oxaliplatin in treatment of 68 cases with advanced clastric cancer

Objective： The aim of this study was to evaluate the response rate, time to progression （TTP）, overall survival, and safety of the combination of capecitabine plus oxaliplatin in treatment of advanced gastric cancer （AGC）. Methods： All the patients with advanced gastric cancer who were not received any prior chemotherapy or radiotherapy were treated with combination of capecitabine （1250 mg/m2 twice daily, days 1-14） plus oxaliplatin （130 mg/m2 as a 2-h intravenous infusion on day 1） every 3 weeks. Results： Two cases of complete response （CR） and 34 cases of partial response （PR） were confirmed, giving an overall response rate of 52.9%, of the 68 patients with advanced gastric cancer. The median TTP and overall survival for all patients were 7.3 and 11.9 months, respectively. Grade 3 leukopenia, thrombocytopenia, nausea/vomiting, and diarrhea were observed in 3, 5, 1, and 4 patients, respectively. Yet, no grade 4 toxicity was observed. Conclusion： Capecitabine/ oxaliplatin combination chemotherapy is active in patients with advanced gastric cancer.     

A clinical study of combination of radiotherapy and IP regimen in the treatment of patients with local advanced esophageal cancer

Objective： The aim of this study was to study the clinical efficacy and toxicity of combination of the radiotherapy and IP regimen for patients with local advanced esophageal cancer. Methods： Sixty-eight cases of local advanced esophageal cancer were randomized into two groups, simple irradiation group （control group, n = 33） receiving conventional radiotherepy to a total of 60 Gy, combined group （research group, n = 35） which received the same radiotherapy as simple irradiation group ptus chemotherapy with IP regimen, patients in research group were treated with infusion of Irinotecan 65 mg/m^2 and DDP 30 mg/m^2 on days 1 and 8. Twenty-one days was a cycle and 4 cycles were given. Results： The remission rate, one and two year disease-free survival rate in research group were significant higher than it in control group. But the incidence of nausea, vomiting, myelosuppression and diarrhea was higher in research group. Conclusion： The efficacy of concomitant radiotherapy and IP regimen for local advanced esophageal cancer is obviously and it can improve the survival rate of patients, which worthy of clinical application.     

The effect of different inflation volumes of laryngeal mask airway on efficacy of closed circuit controlled ventilation in pediatric cancer patients

Objective： The laryngeal mask airway （LMA） is an established way for airway control during spontaneous ventila- tion. Its ability to deliver positive pressure ventilation without leakage especially in low flow states is still controversy. The aim of this study is to test the possibility of using LMA in pediatric closed circuit controlled ventilation, and to find out the optimum cuff volume to perform closed system ventilation. Methods： Twenty children scheduled for elective surgeries were enrolled in a crossover study. Laryngeal mask airway was used. In stage I, the cuff was inflated with the maximum volume of air as rec- ommended by the manufacturers. Adjustment of volume of air inflated into the LMA cuff to the minimum volume to obtain the effective seal was done at stage II. The leak pressure, intracuff pressure and the leak volume were measured in both stages. Results： The cuff filling volume was significantly lower compared to the maximum cuff inflation volume in stage I. Leakage values showed significantly less values in stage II of the study with smaller cuff inflation volumes. The airway leakage pressure was significantly lower in stage fl in comparison to stage I. Cuff inflation pressure in stage I showed marked elevation which dropped significantly after adjustment of cuff volume in stage I1. Conclusion： Laryngeal mask airway is an effective tool to provide closed circuit controlled ventilation in pediatrics. Inflation of the cuff by the minimum volume of air needed to reach the just sealing pressure is suggested to minimize the leakage volume.     

The effect of Jinlong capsule on the immune function for intervened patients with primary liver cancer

Objective： The aim of this study was to evaluate the effect of Jinlong capsule on the immune function for inter- vened patients with primary liver cancer. Methods： Matched the inclusion criteria, 60 patients were selected and randomly divided into two groups. The treatment group had 30 cases treated with Jinlong capsule combined with the transcatheter arterial chemoembolization （TACE）; the control group had 30 cases treated with TACE. Each group was treated 30 days as a cycle, which had completed at least two cycles. Indicators of cellular immune function about the activity of CD3, CD4, CD8, CD4/CD8 and natural killer （NK） cell were detected before and after treatment, then to compare and analysis with each other. Results： Before treatment, the activity of peripheral blood CD3, CD4, CD8, CD4/CD8 and NK cell in the two groups was no significant difference （P 〉 0.05）; after treatment, the activity of CD3, CD4 and NK cell in the treatment group was significantly increased, the ratio of CD4/CD8 increased, and the value of CD8 decreased （P 〈 0.05）, the activity of CD3, CD4 and NK cell in the control group was significantly decreased, the ratio of CD4/CD8 decreased （P 〈 0.05）, and the value of CD8 slightly higher than before treatment （P 〉 0.05）, the difference between the two groups indicated the statistical significance （P 〈 0.05）. Incidence of gastrointestinal reactions, leucopenia, hemoglobin, platelet decline in the treatment group was lower than those in the control group, but without presenting the statistical significance （P 〉 0.05）. Conclusion： Jinlong capsule with hepatic arterial infusion chemotherapy can improve the patients＇ immune function, and reduce the adverse reactions of interventional chemotherapy. Hence, it deserves to be promoted in clinically.     

The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting

Objective： We aimed to evaluate the effect of bevacizumab in the palliative treatment of Chinese metastatic colorectal cancer （mCRC） and its efficacy in different lines. Methods： Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2005 to 2013 were recruited as the study group and control group. The endpoints were objective response rate （ORR）, disease control rate （DCR）, overall survival （OS） and progression free survival （PFS）. The OS and PFS of first-, second- and third-line treatment groups were compared between study group and control group. Re- sults： The median PFS of the study and the control group were 8.2 months （7.0-9.4 months）, 5.7 months （4.7-6.6 months）, P = 0.001; OS were 26 months （5.4-130.5 months）, 18 months （16.6-19.4 months）, P 〈 0.001, respectively. The ORR and DCR of first-, second- and third-line were 30.3% （20/66）, 20% （6/30）, 17.6% （3/17） and 97% （64/66）, 86.7% （26/30）, 100% （17/17）. In the first-line chemotherapy group, the OS of the study group and the control group were 22.9 （5.4-96.7） months and 18 （16.6-19.4） months （P 〈 0.001）; PFS were 9.4 （8.4-10.4） months and 5.7 （4.7-6.6） months （P 〈 0.001）, respectively. While in the second- and third-line setting, only OS were statistically different, PFS had no significant difference. Conclusion： The combination of bevacizumab and chemotherapy had a promising short-term and long-term efficacy in Chinese mCRC patients than those without bevacizumab regimens, and the effect could be better reflected in the first-line treatment.     

Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer

Objective： We observe the curative effect, median survival time, time to progression, quality of life and adverse effect of patients with advanced refractory non-small cell lung cancer （NSCLC） after gefitinib （Iressa） treatment. Methods： Forty-one patients with grade Ⅲb to Ⅳ NSCLC previously treated with two chemotherapy including 85.4% of patients after second line therapy were chosen. The regimen was oral intake of gefitinib 250 mg once daily until the disease progression or toxic reaction has become intolerable. The patients were required to receive tumor evaluation before the treatment, one month, two month and every three months after Iressa administration. Results： All of 41 patients were evaluable for therapeutic effect. Without complete regression being observed, partial response rate （PR）, stable disease （SD） and progression of disease （PD） were 43.9% （18/41）, 34.1% （14/41） and 22.1% （9/41）, respectively. The overall response rate was 43.9% （18141） and disease control rate （PR ＋ SD） was 78% （32/41）. The response rate in male was 42.1%, while it in female was 45.5% （P 〉 0.05）. Twenty-two of them （53.7%, 22/41） were still alive with 10.1 months of MST when the follow-up ended in November 2006. TTP and MST of patients who died was 2.7 and 5.0 months, respectively. The rate of symptom improvement was 78% of all patients with 13 months of MST of PR patients. The Karnofsky enhanced 20 ＋ 5 after 28 days treatment without 3-4 degree of reactive toxicity. Conclusion： Iressa has significant antitumor activity in advanced NSCLC patients who have previously failed in second or third line chemotherapy. Iressa is effective and safe for patients with poor performance status.